Ginkgo bioworks to expand platform capabilities in agricultural biologicals and launch flagship partnership with bayer

Planned transaction expands ginkgo's horizontal platform capabilities to support agricultural biologicals r&d from discovery through formulation and early field trials and will offer services to customers of all sizes in the agriculture industry under the proposed transaction, ginkgo to acquire bayer's west sacramento agricultural biologicals site and team, adding a 175,000-square-foot r&d facility with pilot scale fermentation, formulation, and greenhouse facilities, along with access to bayer's large agricultural strain collection joyn bio, the joint-venture between ginkgo and leaps by bayer formed in 2017, to be integrated into the parent companies, with the core technology platform becoming part of ginkgo's platform and key products being advanced by bayer in a new collaboration bayer to be an anchor customer of ginkgo's agricultural biologicals offering, signing a follow-on multi-year platform collaboration deal to enable continued development of joyn bio's flagship nitrogen fixation program and launching new programs in fields including next-generation crop protection and carbon sequestration boston , april 22, 2022 /prnewswire/ -- ginkgo bioworks (nyse: dna), the leading horizontal platform for cell programming, today announced plans to significantly expand its platform capabilities in agricultural biologicals, from discovery to field. these capabilities will be built through a series of transactions, in which ginkgo will acquire bayer's 175,000-square-foot west sacramento biologics research & development site, team, and internal discovery and lead optimization platform as well as integrate the r&d platform assets from joyn bio, a joint-venture between ginkgo and leaps by bayer formed in 2017.
DNA Ratings Summary
DNA Quant Ranking